Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) have earned a consensus recommendation of “Moderate Buy” from the ten research firms that are presently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell rating, six have issued a buy rating and two have given a strong buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $43.7143.

A number of brokerages have commented on CRBP. Oppenheimer lifted their price target on Corbus Pharmaceuticals from $53.00 to $57.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 10th. Jefferies Financial Group raised Corbus Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, February 18th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Corbus Pharmaceuticals in a research report on Wednesday, January 21st.

Corbus Pharmaceuticals Stock Performance

Shares of CRBP opened at $9.71 on Wednesday. The stock has a 50-day moving average of $8.56 and a two-hundred day moving average of $10.43. Corbus Pharmaceuticals has a one year low of $5.12 and a one year high of $20.56. The stock has a market cap of $172.22 million, a P/E ratio of -1.62 and a beta of 2.78.

Corbus Pharmaceuticals (NASDAQ:CRBP) last issued its quarterly earnings results on Monday, March 9th. The biopharmaceutical company reported ($1.25) EPS for the quarter, topping analysts’ consensus estimates of ($1.78) by $0.53. Analysts predict that Corbus Pharmaceuticals will post -4.23 EPS for the current fiscal year.

Insider Buying and Selling

In other Corbus Pharmaceuticals news, insider Dominic Smethurst sold 3,285 shares of Corbus Pharmaceuticals stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $8.09, for a total transaction of $26,575.65. Following the completion of the sale, the insider owned 95,887 shares of the company’s stock, valued at approximately $775,725.83. The trade was a 3.31% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 4.00% of the company’s stock.

Hedge Funds Weigh In On Corbus Pharmaceuticals

A number of institutional investors have recently modified their holdings of the stock. Velan Capital Investment Management LP raised its stake in shares of Corbus Pharmaceuticals by 3.4% during the 3rd quarter. Velan Capital Investment Management LP now owns 61,000 shares of the biopharmaceutical company’s stock valued at $772,000 after buying an additional 2,000 shares during the last quarter. Mariner LLC raised its stake in shares of Corbus Pharmaceuticals by 34.0% during the 3rd quarter. Mariner LLC now owns 20,840 shares of the biopharmaceutical company’s stock valued at $264,000 after buying an additional 5,289 shares during the last quarter. Persistent Asset Partners Ltd purchased a new position in shares of Corbus Pharmaceuticals during the 4th quarter valued at about $54,000. ADAR1 Capital Management LLC purchased a new position in shares of Corbus Pharmaceuticals during the 3rd quarter valued at about $129,000. Finally, Virtu Financial LLC purchased a new position in shares of Corbus Pharmaceuticals during the 4th quarter valued at about $88,000. Hedge funds and other institutional investors own 64.64% of the company’s stock.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company’s lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body’s innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.

Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation.